Smellprints in lung Cancer; the role of ENose in diagnosis and Treatment (SCENT): part 3. Acute effects on smellprints of chemotherapy in patients with lung cancer.

Completed

Conditions: lung cancer or bronchial carcinoma
10029107

Registration Number: NL-OMON32493

Lead Sponsor: Medisch Centrum Leeuwarden

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 75

Inclusion Criteria

-Informed consent is obtained.
-newly diagnosed adenocarcinoma or squamous cell carcinoma stage IIIA, IIIB or IV or small cell lung cancer)
-Adults 18-80 years.
-scheduled for chemotherapy as first part of the treatment:
Cisplatin/Gemcitabine (NSCLC) and Cisplatin/Etoposide (SCLC)

Exclusion Criteria

-Previous chemotherapy
-unable to evaluate response with the RECIST criteria.
-unable to follow the instructions for the eNose measurement
-eating, drinking and smoking < 3 hours prior to measurement

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Difference in smellprints of exhaled breath provided by the eNose before and<br /><br>after chemotherapy.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-ad a: difference in smellprints of exhaled breath provided by the eNose<br /><br>between distinct subgroups of lung cancer (adenocarcinoma vs sqamous cell<br /><br>carcinoma vs SCLC)<br /><br>-ad b: relationship between smellprints and stage of lung cancer or SUV on<br /><br>18FDG-PET (see objectives).<br /><br>-ad c: relationship between smellprints and tumour response classified<br /><br>according to the RECIST [3] criteria </p><br>